Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Bucharest – page 2

660 clinical trials in Bucharest, Romania across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Bucharest at a glance
660
clinical trials
  • Research sites19
Type of trial
Recruitment status
Quick filters

660 trials in Bucharest

Open in trial search

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:XMAB942
  • Sponsor:Xencor Inc.

COVID-19

Recruiting

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Molnupiravir
  • Sponsor:Merck Sharp & Dohme LLC

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Orforglipron for stress urinary incontinence in women with obesity or overweight

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Sponsor:Eli Lilly & Co.

Other cities in Romania

The busiest research cities in the country

All 65 cities in Romania

Clinical research in Bucharest

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Bucuresti includes a strong focus on cardiovascular diseases, with studies targeting atherosclerotic risk and event prevention in high-risk patients.

  • Atherosclerotic cardiovascular disease
  • Primary prevention of ASCVD
  • Risk reduction for major cardiovascular events

These trials are mainly designed to evaluate new approaches that may lower the chance of heart attacks, strokes, and other serious vascular complications.

02 Nervous System Diseases

The nervous system diseases portfolio covers conditions affecting cognition, movement, and headache disorders, reflecting a broad interest in neurological care and symptom control.

  • Agitation associated with Alzheimer’s disease
  • Migraine
  • Episodic migraine

Research here is focused on testing treatments that may improve daily functioning, reduce symptoms, and support long-term management in both adults and pediatric patients.

03 Mental Disorders

Trials in mental disorders are examining new options for people living with schizophrenia, especially those who do not respond well to standard antipsychotic treatment.

  • Schizophrenia
  • Adjunctive symptom management
  • Treatment response in difficult-to-manage psychiatric illness

The overall aim is to better control symptoms and improve treatment effectiveness for patients with ongoing psychiatric needs.

04 Respiratory Tract Diseases

In the area of respiratory tract diseases, studies are centered on moderate-to-severe uncontrolled asthma, with attention on therapies that may offer better symptom control.

  • Moderate-to-severe uncontrolled asthma
  • Symptom relief and disease control
  • Safety and effectiveness of new asthma treatments

These trials are exploring whether investigational therapies can help patients breathe more easily and reduce the burden of persistent asthma.

05 Nutritional and Metabolic Diseases

Research in nutritional and metabolic diseases includes studies on obesity and overweight, as well as related joint problems that often accompany excess body weight.

  • Obesity
  • Overweight
  • Knee osteoarthritis

The goal is to assess therapies that may support weight management and improve associated health outcomes, including joint pain and mobility.

06 Neoplasms

Oncology research in Bucuresti includes trials for limited-stage small cell lung cancer after chemoradiotherapy, with a focus on consolidation treatment strategies.

  • Limited-stage small cell lung cancer
  • Post-chemoradiotherapy disease control
  • Treatment effectiveness in lung cancer

These studies are evaluating whether new immunotherapy combinations can help maintain remission and improve survival outcomes.

07 Neurodegenerative and Psychiatric Symptom Research

Some trials bring together neurology and psychiatry by studying agitation in Alzheimer’s disease, an important symptom that can affect patients and caregivers alike.

  • Agitation associated with Alzheimer’s disease
  • Behavioral symptom management
  • Long-term safety and tolerability

The research is intended to find better ways to manage distressing behavioral symptoms while supporting longer-term treatment use.

08 Inflammation and Renal-Related Research

Another active area involves patients with ESKD undergoing dialysis, where studies are exploring inflammatory markers linked to cardiovascular risk.

  • End-stage kidney disease
  • Dialysis-associated inflammation
  • Reduction of high-sensitivity C-reactive protein

These trials aim to better understand whether new therapies can help reduce inflammation and potentially improve overall health outcomes in this high-risk group.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.